November 21, 2011 (New York, New York) — Three-year follow-up of the RESILIENT trial has shown that the LifeStent vascular stent (Bard Peripheral Vascular) leads to durable benefits and clinical ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio LAS VEGAS — A repuncturable vascular ...

New Clinical Data Presented for First Time at Medical Meetings in U.S. and Europe Show Durable Vessel Patency in Treating Atherosclerotic Lesions of Superficial Femoral Artery MINNEAPOLIS –– ...

The FDA today approved Cook Medical's Zilver PTX stent. It is the first drug-eluting stent (DES) approved for the treatment of peripheral arterial disease (PAD) in the superficial femoral and proximal ...

Cordis, a unit of Johnson & Johnson ($JNJ) is seeking an expanded indication for its SMART self-expanding stent, and the device performed well in patients with ...

Endovascular therapy, compared with surgery, was associated with significantly lower perioperative morbidity and mortality in patients with de novo atherosclerotic lesions of the common femoral artery ...

A drug-coated stent from Bloomington-based Cook Medical met safety and effectiveness goals in the treatment of blocked femoral arteries, according to a staff report by U.S. regulators weighing whether ...

BLOOMINGTON, Ind.--(BUSINESS WIRE)--Cook Medical introduced the results from an aggregated data analysis at the Vascular Interventional Advances (VIVA) conference, highlighting the Zilver ® PTX ® Drug ...

LEIPZIG, GERMANY—What’s the best course of corrective action for obstructive lesions of the common femoral artery (CFA) caused by PAD? At LINC 2020, two experts took to the main stage to debate this ...

IRVINE, Calif.--(BUSINESS WIRE)--Endologix LLC, a privately held, global medical device company dedicated to providing disruptive therapies for the interventional treatment of vascular disease, ...